Treatment of Dyslipidemia in Patients with Renal Insufficiency and End-Stage Renal Disease

We investigated the pharmacokinetics of non-metabolized cefotaxime in 10 patients undergoing CAPD. The elimination half-life after IV administration of I g cefotaxime was 3.1 ± 1.3 hr, i.e. two to three times longer than in individuals with normal renal function but similar to patients with severe renal insufficiency. An average of 2.18% of the dose was recovered in the effluent. The halflife of I g cefotaxime administered in the dialysis solutions was 1.4 ± 0.8 hr. This difference between the half-lives after intraperitoneal and intravenous administration indicates a faster transport through the peritoneal membrane. Intraperitoneally administered cefotaxime -250 mg four times daily, was effective in the treatment of peritonitis in three CAPD patients. Since its introduction in 1976, CAPD has become an effective therapy for end-stage renal disease. The most serious complication is peritonitis and effective treatment is essential. Cefotaxime, a new broad-spectrurn cephalosporin, is active against most gramnegative and gram-positive organisms. It possesses no nephrotoxicity and may be useful in the treatment of peritonitis and other infections in patients on CAPD. This study was done to evaluate the pharmacokinetics of cefotaxime administered intravenously and intraperitoneally during CAPD.

Download Full-text

Which bone age in chronic renal insufficiency and end-stage renal disease?

Pediatric Nephrology ◽

10.1007/bf00862591 ◽

1988 ◽

Vol 2 (2) ◽

pp. 200-204 ◽

Cited By ~ 8

Author(s):

David B. Cundall ◽

J. Trevor Brocklebank ◽

John M. H. Buckler

Keyword(s):

Renal Insufficiency ◽

Renal Disease ◽

Chronic Renal Insufficiency ◽

End Stage Renal Disease ◽

Bone Age ◽

Stage Renal Disease ◽

End Stage

Download Full-text

Adverse events with rhGH treatment of patients with chronic renal insufficiency and end-stage renal disease

The Journal of Pediatrics ◽

10.1067/mpd.2003.189 ◽

2003 ◽

Vol 142 (5) ◽

pp. 539-545 ◽

Cited By ~ 68

Author(s):

Richard N. Fine ◽

Martin Ho ◽

Amir Tejani ◽

Sandra Blethen

Keyword(s):

Adverse Events ◽

Renal Insufficiency ◽

Renal Disease ◽

Chronic Renal Insufficiency ◽

End Stage Renal Disease ◽

Stage Renal Disease ◽

End Stage ◽

Rhgh Treatment

Download Full-text

In-hospital mortality of acute myocardial infarction in patients with and without renal dysfunction

Annals of King Edward Medical University ◽

10.21649/akemu.v11i3.1011 ◽

2016 ◽

Vol 11 (3) ◽

Author(s):

Abdul Rehman Abid ◽

Muhammad Tahir Mohyuddin ◽

Liaqat Ali ◽

Muhammad Shahid Naveed ◽

Nadeem Hayat Mallick

Keyword(s):

Myocardial Infarction ◽

Acute Myocardial Infarction ◽

Renal Insufficiency ◽

Renal Disease ◽

Hospital Mortality ◽

Renal Dysfunction ◽

End Stage Renal Disease ◽

Study Population ◽

Stage Renal Disease ◽

End Stage

Objective: To compare in-hospital mortality of acute myocardial Infarction in patients having normal renal functions with renal dysfunction patients. Setting: Emergency ward, Coronary care units and cardiology wards of the Punjab Institute of Cardiology Lahore. Study design: It was a comparative study. Sample size: 1000 consecutive patients presenting with acute myocardial infarction admitted to the Punjab Institute of cardiology Lahore were studied from 1st March 2004 to 15th August 2004. Results: After fulfilling the inclusion criteria 1000 patients were studied. The mean age of the study population was 60.8+9.38 years. Total number of males in the study population was 642(64.2%) while female patients were 358(35.8%). Patients with any degree of renal dysfunction, except those with end-stage renal disease were more likely to present with anterior MI than were patients without renal dysfunction. Patients with end-stage renal disease and more severe renal dysfunction were more likely to develop heart failure during hospitalization, to experience atrial fibrillation, and to have mechanical complications. Streptokinase therapy was used less frequently in patients with any degree of renal dysfunction than in patients without renal dysfunction, despite a similar incidence of MI. In-hospital mortality was 51(12%) in Group I patients, 46(16.6%) in Group II patients, 36(22%) in Group III patients, 35(27.7%) in Group IV patients and 5(35.7%) in Group V patients with a p value of <0.0001. Severe renal insufficiency had the maximum in-hospital mortality with OR of 5.4 and 95% confidence interval of 2.9-10.3 followed by end stage renal disease OR 5.1 (CI 2.2-12.1), moderate renal insufficiency OR 4.1 (CI 2.3-7.2) and mild renal insufficiency OR 1.9(CI 1.1-3.1) with a p value of <0.0001. Similarly congestive heart failure during hospital stay was observed in 20(4.7%) patients in Group I, 17(6.1%) patients in Group II, 15(9.4%) patients in Group III, 16(12.6%) patients in Group IV and 4(28.6%) patients in Group V. Similar trends were observed in mechanical complications and post myocardial arrhythmias in the study population, Conclusion: Patients with renal dysfunction who have acute MI are a high-risk population and suffer from increased mortality once they are admitted to the hospital. This is because of presence of more risk factors in this sub set of patients.

Download Full-text